A Phase 2 interventional study of Subcutaneous Blinatumomab in CD19 Positive and Mixed Phenotype Acute Leukemia (MPAL), sponsored by West Virginia University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by West Virginia University · Phase 2, Interventional, and Treatment
This is a multicenter, non-randomized, open-label, phase II study evaluating blinatumomab administered subcutaneously in adult subjects with CD19+ MPAL. This trial consists of three cohorts of patients with CD19-positive MPAL, categorized as follows: 1. Cohort A: Newly diagnosed CD19+ MPAL in untreated patients who are either ≥ 75 years of age or have at least one coexisting condition precluding intensive chemotherapy. 2. Cohort B: Patients with CD19+ MPAL who have achieved complete remission (CR, CRh, or CRi) following at least one line of treatment but have detectable measurable residual disease (MRD) at a level of ≥ 0.1%, assessed using an assay with a minimum sensitivity of 0.01%. 3. Cohort C: Patients with CD19+ MPAL with morphologic relapsed or refractory (R/R) disease following at least one prior line of treatment. The Primary Objectives for each cohort are for Cohort A: to evaluate the efficacy of SC-blinatumomab in treatment; for Cohort B: to assess the ability of SC-blinatumomab to achieve MRD-negative CR; for Cohort C: to determine the efficacy of SC-blinatumomab in inducing CR, CRh, or CRi in patients.
At specified time points, subjects will undergo the following procedures: collection of informed consent, medical history, demographics, ECOG performance, and physical exam including vital signs as well as neurological examination including examination of writing ability. Subjects will provide samples for complete blood count with differential and blood chemistry profile, have a bone marrow aspiration and biopsy and lumbar puncture will be performed per protocol or if clinically indicated, and/or ECG, Echocardiography, pulmonary function test will be performed only if medically indicated.
The subcutaneous treatment will be given in both the inpatient and outpatient setting. For an individual subject the length of participation includes up to a 3-week screening period, up to a 13-month treatment period, and a safety follow-up visit (30 days after the last dose of study treatment), and a follow-up period.
110 studies on the registry are indexed under Leukemia, Biphenotypic, Acute; 51 are open to participants now.
This study's planned enrollment of 78 is above the median of 50 across 98 interventional studies indexed under Leukemia, Biphenotypic, Acute.
Browse Leukemia, Biphenotypic, Acute studies →West Virginia University is the lead sponsor of 155 studies on the registry; 35 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.
Counted across the registry records on this site, refreshed daily.
General Criteria for all three Cohorts
Specific Criteria for Cohort A
o Subjects should be ineligible for available induction therapy either if they are 75 years of age or older or if they have at least one of the following coexisting conditions precluding intensive chemotherapy: a history of CHF for which treatment is warranted or a report of EF ≤50% in the last 12 months, a history of chronic stable angina, a report of DLCO of ≤65% or FEV1 ≤65% in the last 12 months, ECOG performance status 3 or 4, Charlson comorbidity index (CCI) ≥3.
Specific Criteria for Cohort B
Subjects must have organ function as below:
Specific Criteria for Cohort C
Subjects must have organ function as below:
Criteria for all three Cohorts
Cohort A: Evaluate the efficacy of SC-blinatumomab in treating newly diagnosed CD19+ MPAL in patients ≥ 75 years old or those deemed unfit for intensive chemotherapy. * Each cycle = 34 days (26-day treatment period + 8-day treatment free interval between day 27 and day 34). * Cycle 1 receives treatment daily during the first week and 3 times (TIW) weekly (M/W/F) during weeks 2-4. * In subsequent cycles, the treatment will be administered TIW during weeks 1-4. * All subjects will be hospitalized for days 1-12 of cycle 1. * Other treatment doses will be given as outpatients. Subjects will remain in the outpatient department for 1-6 hours after each dose is given. * Treatment will be given with ability to delay cycle initiation based on blood counts or general physical/neurological examination findings per clinical indication and institutional standard practice.
Drug: Subcutaneous Blinatumomab
Cohort B: Assess the ability of SC-blinatumomab to achieve MRD-negative CR in patients with CD19+ MPAL in CR/CRh/CRi with persistent MRD positivity (≥ 0.1%) after at least one line of treatment. * Each cycle = 34 days (26-day treatment period + 8-day treatment free interval between day 27 and day 34). * Cycle 1 receives treatment daily during the first week and 3 times (TIW) weekly (M/W/F) during weeks 2-4. * In subsequent cycles, the treatment will be administered TIW during weeks 1-4. * All subjects will be hospitalized for days 1-12 of cycle 1. * Other treatment doses will be given as outpatients. Subjects will remain in the outpatient department for 1-6 hours after each dose is given. * Treatment will be given with ability to delay cycle initiation based on blood counts or general physical/neurological examination findings per clinical indication and institutional standard practice.
Drug: Subcutaneous Blinatumomab
Cohort C: Determine the efficacy of SC-blinatumomab in inducing CR, CRh, or CRi in patients with morphologic relapsed or refractory CD19+ MPAL. * Each cycle = 34 days (26-day treatment period + 8-day treatment free interval between day 27 and day 34). * Cycle 1 receives treatment daily during the first week and 3 times (TIW) weekly (M/W/F) during weeks 2-4. * In subsequent cycles, the treatment will be administered TIW during weeks 1-4. * All subjects will be hospitalized for days 1-12 of cycle 1. * Other treatment doses will be given as outpatients. Subjects will remain in the outpatient department for 1-6 hours after each dose is given. * Treatment will be given with ability to delay cycle initiation based on blood counts or general physical/neurological examination findings per clinical indication and institutional standard practice.
Drug: Subcutaneous Blinatumomab
Blinatumomab will be administered as a subcutaneous (SC) injection.
Also known as: Blincyto®
Cohort A - Overall Survival
The Overall Survival (OS) is the time from treatment initiation to death from any cause.
Time frame: Up to 3 years
Cohort B - Rate of Complete Remission (CR), Complete Remission with Partial Hematological Recovery (CRh), or Complete Remission with Incomplete Hematological Recovery (CRi) with Minimal Residual Disease (MRD) negativity
The rate of achievement of complete remission (CR/CRh/CRi) with MRD-negativity (\<0.01%) after the first two cycles of therapy with blinatumomab. CR: Bone marrow blasts \<5%; absence of circulating blasts; absence of extramedullary disease; absolute neutrophil count (ANC) ≥1000/µL and platelets ≥100,000/µL; MRD+ or unknown. CR +CRh: Bone marrow blasts \<5%; absence of circulating blasts; absence of extramedullary disease; ANC ≥500/µL AND platelet count ≥50,000/µL. CR +CRi: Bone marrow blasts \<5%; absence of circulating blasts; absence of extramedullary disease; with residual thrombocytopenia (platelet count of \<100,000/µL) OR residual neutropenia (ANC \<1000/µL); not fulfilling criteria for CRh. MRD Negativity: No detectable cancer cells using sensitive tests, with less than 0.01% cancer cells. MRD positivity indicates a higher risk of relapse, while MRD negativity is linked to long-term remission and survival benefits.
Time frame: At completion of 2 cycles (each cycle is 34 days)
Cohort C - Rate of Complete Remission (CR) or Complete Remission with Partial Hematological Recovery (CRh)
The rate of achievement of complete remission (CR/CRh) after the first two cycles of therapy with blinatumomab. Complete Remission (CR): No detectable cancer cells in the bone marrow (less than 5% blast cells) and normal blood counts. CRh: No detectable cancer cells, with partial recovery of blood counts (ANC 500-1,000/µL, platelets 50,000-100,000/µL). The rate of achieving these states is calculated by the proportion of patients who reach CR/CRh within a set time. Higher rates of achievement indicate that a larger proportion of participants are responding positively to the treatment, with no detectable cancer cells in their bone marrow and recovery of blood counts.
Time frame: At completion of 2 cycles (each cycle is 34 days)
Cohort A - MRD-negative CR + CRh rate
MRD-negative CR + CRh rate is the proportion of participants who achieve either Complete Remission (CR) or Complete Remission with Partial Hematological Recovery (CRh) and also have no detectable minimal residual disease (MRD) in bone marrow. Higher rates of MRD-negative CR + CRh indicate the treatment is highly effective in both inducing remission and reducing the risk of relapse.
Time frame: At completion of 2 cycles (each cycle is 34 days)
Cohort A - Event-Free Survival (EFS)
Time from treatment initiation to the earliest occurrence of one of the following events: * Failure to achieve CR, CRh, or CRi after at least two cycles of SC-blinatumomab * Relapse after achieving CR, CRh, or CRi * Initiation of new leukemia-directed therapy due to persistent disease or progression * Death from any cause
Time frame: Up to approximately 3 years
Cohort A - Incidence and Severity of Adverse Events (AEs)
The number of AE Incidences including the severity of those events. The descriptions and grading scales found in the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, published on November 27, 2017, will be utilized for AE reporting. The general guidelines for each grade are Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life-threatening), Grade 5 (Death).
Time frame: Up to approximately 1 year
Cohort B - Overall Survival
The Overall Survival (OS)is the time from treatment initiation to death from any cause.
Time frame: Up to approximately 3 years
Cohort B - Rate of MRD-negativity (<0.01%)
The rate of MRD-negativity (\<0.01%) within one cycle of SC-blinatumomab treatment. MRD negativity means that the number of cancer cells is below the threshold of 0.01%. A higher rate of MRD negativity suggests that the treatment is highly effective in eliminating cancer cells and reducing the risk of relapse.
Time frame: At completion of 1 cycle (cycle is 34 days)
Cohort B - Event-Free Survival (EFS)
Time from treatment initiation to the earliest occurrence of one of the following events: * Failure to achieve CR, CRh, or CRi after at least two cycles of SC-blinatumomab * Relapse after achieving CR, CRh, or CRi * Initiation of new leukemia-directed therapy due to persistent disease or progression * Death from any cause
Time frame: Up to approximately 1 year
Cohort B - Incidence and Severity of Adverse Events (AEs)
The number of AE Incidences including the severity of those events. The descriptions and grading scales found in the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, published on November 27, 2017, will be utilized for AE reporting. The general guidelines for each grade are Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life-threatening), Grade 5 (Death).
Time frame: Up to approximately 1 year
Cohort C - Overall Survival
The Overall Survival (OS)is the time from treatment initiation to death from any cause.
Time frame: Up to approximately 3 years
Cohort C - Event-Free Survival (EFS)
Time from treatment initiation to the earliest occurrence of one of the following events: * Failure to achieve CR, CRh, or CRi after at least two cycles of SC-blinatumomab * Relapse after achieving CR, CRh, or CRi * Initiation of new leukemia-directed therapy due to persistent disease or progression * Death from any cause
Time frame: Up to approximately 1 year
Cohort C - Incidence and Severity of Adverse Events (AEs)
The number of AE Incidences including the severity of those events. The descriptions and grading scales found in the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, published on November 27, 2017, will be utilized for AE reporting. The general guidelines for each grade are Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life-threatening), Grade 5 (Death).
Time frame: Up to approximately 1 year
Overall - Incidence and Severity of Adverse Events (AEs)
The number of AE Incidences including the severity of those events. The descriptions and grading scales found in the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, published on November 27, 2017, will be utilized for AE reporting. The general guidelines for each grade are Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life-threatening), Grade 5 (Death).
Time frame: Up to approximately 1 year
Overall - Characterization of Antigen Expression
Assess CD19, CD81, and CD21 expression (levels) in leukemic blasts through flow cytometry and/or immunohistochemical staining to evaluate potential biomarkers of treatment response and resistance. High expression levels may correlate with better treatment outcomes, while low or absent expression may indicate resistance.
Time frame: Up to 10 years
Overall - Frequency of Cytogenetic Abnormalities Identified by Karyotyping and Fluorescence In Situ Hybridization (FISH)
Percentage of patients with identified cytogenetic abnormalities and will be correlated descriptively with clinical outcomes including treatment response, relapse, and overall survival. The frequency and pattern of disease-specific chromosomal abnormalities detected by conventional karyotyping and fluorescence in situ hybridization (FISH) in leukemic blasts.
Time frame: Up to approximately 10 years
Overall - Frequency of Somatic Mutations Identified by Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR)
Percentage of patients with specific genetic alterations and explored for associations with treatment response, relapse patterns, and disease progression. The frequency and spectrum of somatic mutations, gene fusions, or rearrangements detected using next-generation sequencing (NGS) and/or polymerase chain reaction (PCR) in leukemic cells.
Time frame: Up to approximately 10 years
Overall - Transplantation and Cellular Therapy Outcomes
The proportion of subjects proceeding to allogeneic hematopoietic stem cell transplantation (alloHSCT) after SC-blinatumomab treatment, assessing their post-transplant outcomes, relapse rates, and overall survival.
Time frame: Up to approximately 3 years
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Biphenotypic, Acute→
West Virginia University